Patheon Board of Directors Confirms Recommendation that Shareholders Reject Inadequate JLL Offer

    TORONTO, April 28 /CNW/ - Patheon Inc. ("Patheon") (TSX:PTI), today
announced that the Board of Directors has reaffirmed its recommendation that
shareholders reject the unsolicited offer by JLL Patheon Holdings LLC ("JLL")
to acquire, at a price of US$2.00 each, any and all of the issued and
outstanding restricted voting shares of Patheon not owned by JLL or its
affiliates and associates. Each of JLL's three nominees on the Board declared
his conflict of interest and refrained from voting. Directors Joaquin B. Viso
and Wesley P. Wheeler, the Company's Chief Executive Officer, abstained.
    The Board is mailing to Shareholders today a Notice of Change to the
Directors' Circular dated March 25, 2009. The Notice of Change contains
further details regarding the Ontario Securities Commission proceedings that
led to the termination of JLL's side deal with a group of shareholders led by
Mr. Viso, as well as information regarding the Board's reaffirmation of its


    Patheon Inc. (TSX:PTI; is a leading global provider of
contract development and manufacturing services to the global pharmaceutical
industry. Patheon prides itself in providing the highest quality products and
services to more than 300 of the world's leading pharmaceutical and
biotechnology companies. Patheon's services range from preclinical development
through commercial manufacturing of a full array of dosage forms including
parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative
technologies including single-use disposables, Liquid-Filled Hard Capsules and
a variety of modified release technologies.
    Patheon's comprehensive range of fully integrated Pharmaceutical
Development Services includes pre-formulation, formulation, analytical
development, clinical manufacturing, scale-up and commercialization. Patheon
can take customers direct to clinic with global clinical packaging and
distribution services and Patheon's Quick to Clinic(TM) programs can
accelerate early phase development project to clinical trials while minimizing
the consumption of valuable API.
    Patheon's integrated development and manufacturing network of 11
facilities, and 6 development centers across North America and Europe, strives
to ensure that customer products can be launched with confidence anywhere in
the world.

    %SEDAR: 00001700E

For further information:

For further information: Special Committee: Information Agent for the
Special Committee, Kingsdale Shareholder Services, 1-866-851-3212; Media: John
Lute, Lute & Company, (416) 929-5883, email

Organization Profile

Patheon Inc

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890